Antipsychotic News and Research

RSS

Antipsychotics are medicines used to treat the symptoms of mental disorders such as schizophrenia, depression, bipolar disorder (sometimes called manic-depressive illness), anxiety disorders, and attention deficit-hyperactivity disorder (ADHD). Sometimes medications are used with other treatments such as psychotherapy.

Off-label use of AAs among elderly associated with increased risk of diabetes: Study

A new study yields important new evidence that the use of atypical antipsychotics among the elderly for off-label purposes is associated with increased risk of developing diabetes.

14 May 2010

Obesity epidemic may be flattening out - still much to be done

The prevalence of childhood obesity might be stabilising in developed countries, but there is still much to be done to combat this major threat to health, according to a Seminar published on Online First and in an upcoming issue of The Lancet.

6 May 2010

New classification of depressive subtypes of depression proposed

Lichtenberg and Belmaker propose a new classification of depressive subtypes of depression in the current issue of Psychotherapy and Psychosomatics. They argue that a simple diagnosis is no longer sufficient to guide treatment.

3 May 2010

Psychotropic medications common among children with ASD: Research

Behavioral interventions typically are the first line of treatment to manage unwanted behaviors in children with autism spectrum disorders. If behaviors do not improve, medications frequently are added to the mix.

3 May 2010

Astrazeneca settles drug marketing lawsuit, plea deal rejected for possibly defective heart device maker

The New York Times: AstraZeneca has settled a case and agreed to pay $520 million after federal investigations into its marketing practices for a schizophrenia drug, Seroquel. The announcement came Tuesday from Attorney General Eric Holder. Government officials, including Health and Human Services Secretary Kathleen Sebelius, said the company paid illegal kickbacks to doctors to promote drugs for unapproved uses by children, the elderly, veterans and prisoners, which is illegal under federal law.

29 Apr 2010

AstraZeneca to pay $520 million in largest pharmaceutical civil settlement

AstraZeneca will pay the federal government $520 million in civil fines to settle charges of off-label marketing of the powerful antipsychotic drug Seroquel. The settlement is the largest pharmaceutical civil settlement and among the top five civil and criminal drug company settlements in U.S. history.

28 Apr 2010

Researchers receive grant to help people living with mental illness tackle tobacco dependence

Researchers at The University of Nottingham have won government funding to improve the services which help people living with serious mental illness to tackle their tobacco dependence.

22 Apr 2010

Johnson & Johnson' first-quarter 2010 sales increase 4.0% to $15.6 billion

Johnson & Johnson today announced sales of $15.6 billion for the first quarter of 2010, an increase of 4.0% as compared to the first quarter of 2009. Operational results declined 0.1% and the positive impact of currency was 4.1%.

21 Apr 2010

Mylan Pharmaceuticals introduces 50 mg and 200 mg Clozapine Tablets USP

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has launched Clozapine Tablets USP, 50 mg and 200 mg.

19 Apr 2010

SAMHSA study shows how psychiatric drugs prescribed for medical conditions

A new study sponsored by the Substance Abuse and Mental Health Services Administration outlines the conditions that physicians around the country reported treating with psychiatric drugs such as antipsychotics, antidepressants, and anti-anxiety drugs.

23 Mar 2010

DSPA's lurasidone NDA accepted for FDA review

Dainippon Sumitomo Pharma America, Inc., a U.S. subsidiary of Dainippon Sumitomo Pharma Co., Ltd., today announced that the U.S. Food and Drug Administration recently accepted for review the lurasidone New Drug Application (NDA) for the treatment of patients with acute schizophrenia. The NDA was submitted to FDA on December 30, 2009 and will receive a standard review.

10 Mar 2010

Winners of NMSIS scholarship award

Two winners have been selected for the Promising New Investigators Travel Scholarship Awards given annually by the Neuroleptic Malignant Syndrome Information Service (NMSIS).

10 Mar 2010

State Roundup: N.Y. drug pricing, Vermont hospital ads, Massachusetts nursing homes and anti-psychotics

Poughkeepsie Journal: A new report on New York drug prices, "issued by the New York Public Interest Research Group, Consumers Union, the Center for Medical Consumers and AARP, looked at the price of the 10 most popular drugs found in the state's pharmacies provided through a Freedom of Information Law request. The analysis found a drastic price difference in the same drugs offered in different locations" (Campbell, 3/6).

9 Mar 2010

States continue to wrestle with Medicaid spending, budget issues; Utah legislation would criminalize illegal abortion

Cincinnati Business Courier: Ohio Gov. Ted Strickland has signed a bill that will extend the state's mini-COBRA program from 12 to 15 months for small-business employees, according to a report in Columbus Business First (3/1).

2 Mar 2010

USPTO issues notice of allowance for Vanda Pharmaceuticals' Fanapt long-acting injectable formulation

Vanda Pharmaceuticals Inc. announced today that the U.S. Patent and Trademark Office has issued a notice of allowance for its patent application of a microsphere, long-acting injectable formulation of its antipsychotic product, Fanapt™ (iloperidone). When issued, this U.S. patent will expire on October 30, 2022, and in addition, the U.S. Patent and Trademark Office has granted a patent term adjustment of 300 days, leading to an effective expiration date of August 26, 2023.

26 Feb 2010

Genetic link between schizophrenia and autism may help study effectiveness of drugs for both illnesses

A genetic link between schizophrenia and autism is enabling researchers to study the effectiveness of drugs used to treat both illnesses.

24 Feb 2010

Obecure granted patent covering betahistine with olanzapine for mitigating antipsychotic drug associated weight gain

Obecure Ltd., a subsidiary of Bio-Light Israeli Life Science Investments Ltd., has received notice of allowance from the US Patent Office for its two key patent applications covering methods of use and compositions covering the use of betahistine with olanzapine for the mitigation of the serious weight gain associated as a side effect of the antipsychotic drug.

23 Feb 2010

Obecure enters into licensing and clinical supply agreement with Grunenthal's subsidiary for XR betahistine

Obecure Ltd (http://www.obecure.com)., a subsidiary of Bio-Light Israeli Life Science Investments Ltd., announced today the execution of a licensing and clinical supply agreement with Farmaceutici Formenti SPA, the Italian Subsidiary of the Grunenthal Group.

17 Feb 2010

Elan announces fourth-quarter and full-year financial results ended December 31, 2009

Elan Corporation, plc today reported its fourth quarter and full-year 2009 financial results and provides financial guidance for 2010.

10 Feb 2010

Study: Schizophrenia patients may experience beneficial brain changes in response to exercise

Potentially beneficial brain changes (an increase in the volume of an area known as the hippocampus) occur in response to exercise both in patients with schizophrenia and healthy controls, according to a report in the February issue of Archives of General Psychiatry, one of the JAMA/Archives journals.

1 Feb 2010